<DOC>
	<DOCNO>NCT00004902</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness tocladesine treat patient recurrent refractory multiple myeloma .</brief_summary>
	<brief_title>Tocladesine Treating Patients With Recurrent Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety 8-chloro-cyclic adenosine monophosphate ( 8-chloro-cAMP ) patient recurrent refractory multiple myeloma . II . Evaluate efficacy regimen patient . III . Determine pharmacokinetics regimen patient . OUTLINE : Patients receive 8-chloro-cyclic adenosine monophosphate ( 8-chloro-cAMP ) 120 hour every 2 week 4 course . Beginning course 5 , patient stable responsive disease receive 8-chloro-cAMP 120 hour every 3 week disease progression . Patients follow every 3 month death . PROJECTED ACCRUAL : A maximum 29 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>8-chloro-cyclic adenosine monophosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent refractory multiple myeloma Measurable disease monoclonal serum urine globulin OR Malignant plasma cell document bilateral bone marrow biopsy Refractory least one prior therapeutic regimen ( 2 prior regimen allow ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine great 1.5 mg/dL AND/OR Creatinine clearance least 60 mL/min Calcium great 8.7 g/dL Cardiovascular : No history arrhythmias No uncontrolled angina pectoris No symptomatic coronary ischemia No grade 3 4 congestive heart failure Cardiac ejection fraction great 35 % gate image Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy Endocrine therapy : At least 3 week since prior glucocorticoid Radiotherapy : Not specify Surgery : Not specify Other : No concurrent theophylline therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>